Statements and announcements from Patients For Affordable Drugs NOW.
Patients For Affordable Drugs Now Executive Director Merith Basey issued the following statement in response to President Trump’s new Executive Order (EO) on drug pricing:
Press Releases May 2, 2025Patients For Affordable Drugs Now (P4ADNow) and AARP sent a joint letter to key House committee leaders opposing The EPIC Act (H.R. 1492), a bill that would delay when Medicare can negotiate lower…
Press Releases May 1, 2025Patients For Affordable Drugs Now strongly opposes the reintroduction of two harmful patent bills — the PREVAIL Act and the Patent Eligibility Restoration Act — which would further enable abuse of…
Press Releases Mar 14, 2025Patients For Affordable Drugs Now welcomes two bipartisan bills to curb some of Big Pharma’s abuses of the patent system in a renewed effort to lower prescription drug prices.
Press Releases Mar 6, 2025Patients For Affordable Drugs Now applauds the reintroduction of key bipartisan drug price reforms that were left out of the end-of-year package in 2024 due to last-minute political maneuvering.
Press Releases Feb 13, 2025Following a narrow Senate vote, Robert F. Kennedy Jr., was confirmed today as Secretary of the Department of Health and Human Services (HHS).
Press Releases Dec 17, 2024Patients For Affordable Drugs Now (P4ADNow) is pleased to see critical drug pricing reforms included in the health care package attached to the continuing resolution (CR) released today.
Press Releases Nov 6, 2024Following the U.S. Presidential Election being called for Former President Donald Trump, David Mitchell, Founder of Patients For Affordable Drugs Now, issued the following statement:
Press Releases Jul 11, 2024In a major step forward for patients and consumers, the U.S. Senate has unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S-150), to curb abuses of the patent system by…
Press Releases Jul 10, 2024Patients For Affordable Drugs Now (P4ADNow) issued the following statement in response to the Federal Trade Commission’s (FTC) bipartisan interim staff report on Pharmacy Benefit Managers (PBMs):